Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRM5 | P41594 | 1/20 | 0.67 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | NPC1 | O15118 | 7/20 | 0.66 |
| ▸ | RAB9A | P51151 | 7/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.62 |
| ▸ | MEN1 | O00255 | 4/20 | 0.62 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.61 |
| ▸ | NT5E | P21589 | 1/20 | 0.60 |
| ▸ | IDE | P14735 | 1/20 | 0.59 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.58 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.58 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.58 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8555112 | 0.86 | NPC1 (0.72) | GRM5ALDH1A1NPC1RAB9AKMT2A | |
| SCHEMBL822017 | 0.84 | GRM5 (0.85) | GRM5NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL3689257 | 0.83 | RAB9A (0.83) | ALDH1A1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL15305704 | 0.83 | KMT2A (0.65) | GRM5NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL14546718 | 0.82 | NPC1 (0.62) | ALDH1A1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL997866 | 0.82 | RAB9A (0.89) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL29366822 | 0.82 | RAB9A (0.89) | NPC1RAB9AKMT2AMEN1SMN1; SMN2 | |
| SCHEMBL19332885 | 0.82 | NPC1 (0.66) | GRM5NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL7348632 | 0.82 | RAB9A (0.66) | ALDH1A1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL8554924 | 0.82 | ALDH1A1 (0.77) | GRM5ALDH1A1NPC1RAB9AKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2734522-A1 | 4 - IMIDAZOPYRIDAZIN- 1 -YL-BENZAMIDES AND 4 - IMIDAZOTRIAZIN- 1 - YL - BENZAMIDES AS BTK- INHIBITORS | Merck Sharp & Dohme B.V. (NL) | 2014-05-28 | — | — | EP | claimed |
| WO-2013010868-A1 | 4 - IMIDAZOPYRIDAZIN- 1 -YL-BENZAMIDES AND 4 - IMIDAZOTRIAZIN- 1 - YL - BENZAMIDES AS BTK- INHIBITORS | MSD OSS B.V. (NL) | 2013-01-24 | — | — | WO | claimed |
| EP-0815108-A1 | CYCLIC UREA HIV PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-01-07 | — | — | EP | claimed |
| US-5683999-A | Cyclic urea HIV protease inhibitors | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-11-04 | — | — | US | claimed |
| US-20160166553-A1 | ANTIMETASTATIC COMPOUNDS | UNIV BRIGHAM YOUNG (US) | 2016-06-16 | — | — | US | disclosed |
| EP-2734529-A1 | BTK INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2014-05-28 | — | — | EP | disclosed |
| US-20130158035-A1 | ANTIMETASTATIC COMPOUNDS | BRIGHAM YOUNG UNIVERSITY (US) | 2013-06-20 | — | — | US | disclosed |
| WO-2013010380-A1 | BTK INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2013-01-24 | — | — | WO | disclosed |
| EP-0815108-A1 | CYCLIC UREA HIV PROTEASE INHIBITORS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1998-01-07 | — | — | EP | disclosed |
| US-5683999-A | Cyclic urea HIV protease inhibitors | THE DUPONT MERCK PHARMACEUTICAL COMPANY (US) | 1997-11-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130158035-A1 | ANTIMETASTATIC COMPOUNDS | MET, HGFAC, HGF | GRM5 192/4885ALDH1A1 855/4885NPC1 1073/4885 |
| US-20160166553-A1 | ANTIMETASTATIC COMPOUNDS | MET, HGFAC, HGF | GRM5 192/4885ALDH1A1 855/4885NPC1 1073/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.